Is Shanghai Henlius Biotech (SEHK:2696) Fairly Valued? A Fresh Look at Current Market Expectations

Simply Wall St.

Sep 22

Shanghai Henlius Biotech (SEHK:2696) has been catching the attention of investors lately. There has not been a major event driving sudden headlines, but sometimes a period of relative calm can be just...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2569733764"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569733764\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569733764?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-09-22 20:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569733764","market":"us","top_or_hot":-1,"title":"Is Shanghai Henlius Biotech (SEHK:2696) Fairly Valued? A Fresh Look at Current Market Expectations","media":"Simply Wall St.","content":"<div>\n<p>Shanghai Henlius Biotech (SEHK:2696) has been catching the attention of investors lately. There has not been a major event driving sudden headlines, but sometimes a period of relative calm can be just...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/is-shanghai-henlius-biotech-sehk2696-fairly-valued-a-fresh-l\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Shanghai Henlius Biotech (SEHK:2696) Fairly Valued? A Fresh Look at Current Market Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Shanghai Henlius Biotech (SEHK:2696) Fairly Valued? A Fresh Look at Current Market Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-22 20:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/is-shanghai-henlius-biotech-sehk2696-fairly-valued-a-fresh-l><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shanghai Henlius Biotech (SEHK:2696) has been catching the attention of investors lately. There has not been a major event driving sudden headlines, but sometimes a period of relative calm can be just...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/is-shanghai-henlius-biotech-sehk2696-fairly-valued-a-fresh-l\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/is-shanghai-henlius-biotech-sehk2696-fairly-valued-a-fresh-l","article_id":"2569733764","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/is-shanghai-henlius-biotech-sehk2696-fairly-valued-a-fresh-l","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2569733764","pubTimestamp":1758543062,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Shanghai Henlius Biotech (SEHK:2696) has been catching the attention of investors lately. There has not been a major event driving sudden headlines, but sometimes a period of relative calm can be just as telling, prompting new questions about what the market may be expecting from the company in the months ahead.\n\nThe stock’s journey over the last year has been anything but straightforward. While momentum has cooled in the past month, with a 7% dip, the share price is still up more than 2% for...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02696":"复宏汉霖"},"translate_title":"复宏汉霖生物科技（SEHK：2696）的估值是否合理？重新审视当前市场预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1.5},"content_text":"Shanghai Henlius Biotech (SEHK:2696) has been catching the attention of investors lately. There has not been a major event driving sudden headlines, but sometimes a period of relative calm can be just as telling, prompting new questions about what the market may be expecting from the company in the months ahead.\n\nThe stock’s journey over the last year has been anything but straightforward. While momentum has cooled in the past month, with a 7% dip, the share price is still up more than 2% for the year and more than 5% over a three-year period. This contrasts with a quick bounce in the past three months, hinting that investor sentiment may be shifting even without a clear external catalyst.\n\nSo, the big question is: does this quieter patch signal a window for value investors, or is the market already factoring in Shanghai Henlius Biotech’s future growth story?\nAdvertisementPrice-to-Earnings of 46.9x: Is it justified? Shanghai Henlius Biotech is currently trading at a Price-to-Earnings (P/E) ratio of 46.9x. This is higher than the Asian Biotechs industry average of 43.8x and nearly double the estimated fair P/E ratio of 23.1x. This suggests that the market expects future growth, but the premium could be steep compared to benchmarks. The Price-to-Earnings ratio compares a company's share price to its earnings per share and is widely used to assess whether a stock is attractively priced. For biotech companies, where high growth and risk are often present, a higher P/E can reflect optimism for future profitability and innovation. At these levels, the market appears to be pricing in robust performance improvements in the future. Still, investors should consider whether earnings growth is likely to justify such a premium, especially since recent growth has slowed compared to multi-year trends. Result: Fair Value of $133.41 (UNDERVALUED) See our latest analysis for Shanghai Henlius Biotech. However, investors should note that slower earnings growth and the stock’s high valuation could spark volatility if future results fail to meet lofty expectations. Find out about the key risks to this Shanghai Henlius Biotech narrative. Another View: What Does Our DCF Model Say? Looking at the numbers from another angle, the SWS DCF model also points to Shanghai Henlius Biotech being undervalued. However, every method has its limits, and the next move could surprise both camps. Look into how the SWS DCF model arrives at its fair value. 2696 Discounted Cash Flow as at Sep 2025 Stay updated when valuation signals shift by adding Shanghai Henlius Biotech to your watchlist or portfolio. Alternatively, explore our screener to discover other companies that fit your criteria.\n Build Your Own Shanghai Henlius Biotech Narrative If you see things differently or want to run your own numbers, it only takes a few minutes to build a Shanghai Henlius Biotech story from scratch. Do it your way A great starting point for your Shanghai Henlius Biotech research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision. Looking for more investment ideas? There is a world of potential beyond just one stock. Use these top picks from Simply Wall Street’s tools to widen your scope and uncover new opportunities that match your goals. You could miss out if you do not look.  Secure steady income streams and strong yields when you check out dividend stocks with yields > 3%. Catch the next big trend in financial technology by exploring companies in cryptocurrency and blockchain stocks. Spot hidden value among fast-growing, under-the-radar businesses using undervalued stocks based on cash flows.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}